(Press-News.org) Prostate cancer patients whose tumors contain a shortened protein called AR-V7, which can be detected in the blood, are less likely to respond to two widely used drugs for metastatic prostate cancer, according to results of a study led by researchers at the Johns Hopkins Kimmel Cancer Center. If large-scale studies validate the findings, the investigators say men with detectable blood levels of AR-V7 should avoid these two drugs and instead take other medicines to treat their prostate cancer. A report on the work is described online Sept. 3 in the New England Journal of Medicine.
The study evaluated two groups of 31 men with prostate cancer that had spread and whose blood levels of prostate-specific antigen (PSA) were still rising despite low testosterone levels. Investigators gave each man either enzalutamide (Xtandi) or abiraterone (Zytiga) and tracked whether their PSA levels continued to rise, an indication that the drugs were not working. In the enzalutamide group, none of 12 patients whose blood samples tested positive for AR-V7 responded to the drug, compared with 10 responders among 19 men who had no AR-V7 detected. In the abiraterone group, none of six AR-V7-positive patients responded, compared with 17 responders among 25 patients lacking AR-V7.
Enzalutamide and abiraterone have been very successful in lengthening the lives of about 80 percent of patients with metastatic prostate cancer, says Emmanuel Antonarakis, M.D., assistant professor of oncology at Johns Hopkins, but the drugs do not work in the remaining 20 percent of patients.
"Until now, we haven't been able to predict which patients will not respond to these therapies. If our results are confirmed by other researchers, a blood test could use AR-V7 as a biomarker to predict enzalutamide and abiraterone resistance, and let us direct patients who test positive for AR-V7 toward other types of therapy sooner, saving time and money while avoiding futile therapy," says Antonarakis.
Prostate cancer thrives on male sex hormones (or "androgens"), including testosterone. Enzalutamide and abiraterone target proteins called androgen receptors and block the receptors' ability to activate prostate cancer cells. AR-V7 is a shortened form of the androgen receptor that lacks a binding spot targeted by enzalutamide and abiraterone. With no binding spot for the two drugs, AR-V7 is free to manipulate prostate cancer cells' genetic material, which makes the cancer cells grow and spread.
Antonarakis and his colleague Jun Luo, Ph.D., who first identified AR-V7 in 2008, also tracked patients' progression-free survival (the length of time a patient lives with the disease but does not get worse) and overall survival. They found that, in men receiving enzalutamide, progression-free survival was 2.1 months in AR-V7-positive patients and 6.1 months in AR-V7-negative patients, while overall survival was 5.5 months in AR-V7-positive men and up to 9 months in AR-V7-negative men. Similarly, in men receiving abiraterone, progression-free survival was 2.3 months in AR-V7-positive patients and up to 6 months in AR-V7-negative patients, while overall survival was 10.6 months in AR-V7-positive men and up to 12 months in AR-V7-negative men. The investigators caution that most of the study patients had advanced disease and received multiple prior therapies, so their outcomes may not be generalizable to all men with prostate cancer.
"Patients whose blood samples contained AR-V7 got no benefit from either enzalutamide or abiraterone," says Antonarakis. He adds that the shortened AR-V7 protein could appear in patients' blood samples at the very start of therapy or acquired later, after therapy has begun. He says, "This test could be used before starting enzalutamide or abiraterone therapy, and if the test shows the presence of AR-V7, patients may opt for a different therapy. It could also be used to monitor patients receiving enzalutamide or abiraterone for AR-V7, providing an indication these drugs may not work for much longer."
INFORMATION:
The study was funded by the Prostate Cancer Foundation, the Department of Defense, and the National Institutes of Health's National Cancer Institute (CA058236, CA006973).
Other scientists involved in the study were Changxue Lu, Hao Wang, Brandon Luber, Mary Nakazawa, Jeffrey C. Roeser, Yan Chen, Helen L. Fedor, Tamara L. Lotan, Qizhi Zheng, Angelo M. DeMarzo, John T. Isaacs, William B. Isaacs, Rosa Nadal, Channing J. Paller, Samuel R. Denmeade, Michael A. Carducci, and Mario A. Eisenberger from Johns Hopkins; and Yidong Chen and Tabrez A. Mohammad from the University of Texas Health Science Center.
Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is a $7 billion integrated global health enterprise and one of the leading academic health care systems in the United States. JHM unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. JHM's vision, "Together, we will deliver the promise of medicine," is supported by its mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care. Diverse and inclusive, JHM educates medical students, scientists, health care professionals and the public; conducts biomedical research; and provides patient-centered medicine to prevent, diagnose and treat human illness. JHM operates six academic and community hospitals, four suburban health care and surgery centers, and more than 35 Johns Hopkins Community Physicians sites. The Johns Hopkins Hospital, opened in 1889, has been ranked number one in the nation by U.S. News & World Report for 22 years of the survey's 25 year history, most recently in 2013. For more information about Johns Hopkins Medicine, its research, education and clinical programs, and for the latest health, science and research news, visit http://www.hopkinsmedicine.org
Media Contacts:
Vanessa Wasta: 410-614-2916; wasta@jhmi.edu
Amy Mone: 410-614-2915l amone@jhmi.edu
Blood test for 'nicked' protein predicts prostate cancer treatment response
2014-09-04
ELSE PRESS RELEASES FROM THIS DATE:
Airline pilots, cabin crews have higher incidence of melanoma
2014-09-03
Bottom Line: Airline pilots and cabin crews appear to have twice the incidence of melanoma as the general population.
Author: Martina Sanlorenzo, M.D., of the University of California, San Francisco, and colleagues.
Background: Melanoma is a common cancer in the United States; in 2014, 76,100 people will be diagnosed with the skin cancer and 9,710 people will die. Several studies have suggested a higher incidence of melanoma in pilots and flight crew. Flight-based workers are thought to have a greater occupational hazard risk of melanoma because of increased altitude-related ...
Obsessive compulsive disorder diagnosis linked to higher rates of schizophrenia
2014-09-03
Bottom Line: A diagnosis of obsessive-compulsive disorder (OCD) appears to be associated with higher rates of schizophrenia and schizophrenia spectrum disorders.
Authors: Sandra M. Meier, Ph.D., of Aarhus University, Denmark, and colleagues.
Background: OCD and schizophrenia are distinct and infrequently overlapping disorders. But some studies have suggested higher rates of co-existing illness with the two disorders in patients.
How the Study Was Conducted: The authors assessed the potential relationship between the two disorders using data from Danish registers. ...
Genetic 'hotspot' linked to endometrial cancer aggressiveness
2014-09-03
Parents of twins often tell them apart through subtle differences such as facial expression, moles, voice tone and gait. Similarly, physicians treating women with endometrial cancer must be able to distinguish between different versions of this disease form that, on the surface, appear the same.
With endometrial cancer, the most common gynecological cancer in the western world and the fourth most prevalent in the U.S., it can literally be a matter of life and death. Mortality rates from this cancer have nearly tripled in the last 25 years and are thought to be attributed ...
Can sleep loss affect your brain size?
2014-09-03
MINNEAPOLIS – Sleep difficulties may be linked to faster rates of decline in brain volume, according to a study published in the September 3, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Sleep has been proposed to be "the brain's housekeeper", serving to repair and restore the brain.
The study included 147 adults 20 and 84 years old. Researchers examined the link between sleep difficulties, such as having trouble falling asleep or staying asleep at night, and brain volume.
All participants underwent two MRI brain scans, ...
Polyester clothes stink after exercise; cotton, not so much
2014-09-03
Polyester clothes smell worse than cotton, following intensive exercise by their wearers, because bacteria that cause odor grow better on polyester, according to research published ahead of print in the journal Applied and Environmental Microbiology.
In the study, the investigators collected t-shirts from 26 healthy individuals following an intensive, hour-long bicycle spinning session, and incubated the shirts for 28 hours before having them inspected by a trained odor panel. The researchers also investigated the taxonomy of the bacteria on the shirts, and in the axillaries. ...
NASA's HS3 hurricane mission and Terra satellite take on Tropical Storm Dolly
2014-09-03
NASA has Tropical Storm Dolly covered by satellite and the remotely piloted Global Hawk aircraft. Both captured data on Dolly before it made landfall in eastern Mexico.
The MODIS or Moderate Resolution Imaging Spectroradiometer instrument aboard NASA's Terra satellite took an image of Tropical Storms Norbert in the Eastern Pacific and Dolly in the Gulf of Mexico at 1:30 p.m. EDT on Sept. 2. The image showed Dolly is a much more organized storm than Norbert, and revealed Dolly's strongest, towering thunderstorms around the center of circulation. Norbert is close to the ...
Researchers discover new clues to determining the solar cycle
2014-09-03
Approximately every 11 years, the sun undergoes a complete personality change from quiet and calm to violently active. The height of the sun's activity, known as solar maximum, is a time of numerous sunspots, punctuated with profound eruptions that send radiation and solar particles out into the far reaches of space.
However, the timing of the solar cycle is far from precise. Since humans began regularly recording sunspots in the 17th century, the time between successive solar maxima has been as short as nine years, but as long as 14, making it hard to determine its cause. ...
NASA sees Tropical Storm Norbert affecting Mexico's west coast
2014-09-03
Tropical Storm Norbert has now triggered Tropical Storm Warnings for Mexico's West Coast, and NASA's Terra satellite showed how close it is to land.
On Wednesday, September 3, the National Hurricane Center (NHC) issued a Tropical Storm Warning from La Paz to Santa Fe, Mexico. There is also a Tropical Storm Watch in effect from north of Santa Fe northward to Cabo San Lazaro, Mexico.
he MODIS or Moderate Resolution Imaging Spectroradiometer instrument aboard NASA's Terra satellite took an image of Tropical Storms Norbert in the Eastern Pacific and Dolly in the Gulf of ...
Climate change science aided by huge but 'invisible' efforts of amateurs
2014-09-03
Ithaca, N.Y.— Hundreds of thousands of volunteer data collectors are due for some thanks from scientists, according to a new paper that reveals the role of citizen science in studies of birds and climate change. Data collected by amateurs underpins up to 77 percent of the studies in this field, but that fact is largely invisible by the time the research appears in journals, according to a study published today in the open-access journal PLOS ONE:
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0106508
"Our paper is a chance to say thank you to the ...
Forming consensus in social networks
2014-09-03
CORAL GABLES, Fla. (Sept. 3, 2014) -- Social networks have become a dominant force in society. Family, friends, peers, community leaders and media communicators are all part of people's social networks. Individuals within a network may have different opinions on important issues, but it's their collective actions that determine the path society takes.
To understand the process through which we operate as a group, and to explain why we do what we do, researchers have developed a novel computational model and the corresponding conditions for reaching consensus in a wide ...